Last reviewed · How we verify
VM-1500A-LAI
VM-1500A-LAI is a Small molecule drug developed by Viriom. It is currently in Phase 2 development. Also known as: VM-1500A, VM-1500, ELPIDA®, Depulfavirine.
VM-1500A-LAI is a small molecule used in the treatment of HIV-1 infection. It is being studied in a clinical trial as a potential switch from standard of care therapy for patients with HIV-1 infection.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VM-1500A-LAI |
|---|---|
| Also known as | VM-1500A, VM-1500, ELPIDA®, Depulfavirine |
| Sponsor | Viriom |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy (PHASE2, PHASE3)
- Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA® (PHASE1, PHASE2)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VM-1500A-LAI CI brief — competitive landscape report
- VM-1500A-LAI updates RSS · CI watch RSS
- Viriom portfolio CI
Frequently asked questions about VM-1500A-LAI
What is VM-1500A-LAI?
Who makes VM-1500A-LAI?
Is VM-1500A-LAI also known as anything else?
What development phase is VM-1500A-LAI in?
Related
- Manufacturer: Viriom — full pipeline
- Also known as: VM-1500A, VM-1500, ELPIDA®, Depulfavirine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing